EVIO (EVIO) FCF Margin %: -8.96% (As of Jun. 2020)


What is EVIO FCF Margin %?

EVIO EVIO -98.00% FCF Margin % is -8.96% as of Jun. 2020.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. EVIO's Free Cash Flow for the three months ended in Jun. 2020 was $-0.05 Mil. EVIO's Revenue for the three months ended in Jun. 2020 was $0.60 Mil. Therefore, EVIO's FCF Margin % for the quarter that ended in Jun. 2020 was -8.96%.

As of today, EVIO's current FCF Yield % is -2,385.71%.

The historical rank and industry rank for EVIO's FCF Margin % or its related term are showing as below:

EVIO' s FCF Margin % Range Over the Past 10 Years
Min: -14.03   Med: 0   Max: 0
Current: -14.03

EVIO's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.51 vs EVIO: -14.03

EVIO FCF Margin % Related Terms

EVIO FCF Margin % Historical Data

* Premium members only.

The historical data trend for EVIO's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EVIO FCF Margin % Chart

EVIO Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19
FCF Margin %
-160.80 -51.69 -27.84 -171.51 -76.91

EVIO Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -141.05 38.64 6.68 -95.85 -8.96

EVIO vs VCBD, ACCA, LITH: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EVIO's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EVIO FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EVIO's FCF Margin % distribution charts can be found below:

* The bar in red indicates where EVIO's FCF Margin % falls into.


EVIO FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

EVIO's FCF Margin for the fiscal year that ended in Sep. 2019 is calculated as

FCF Margin=Free Cash Flow (A: Sep. 2019 )/Revenue (A: Sep. 2019 )
=-2.915/3.79
=-76.91 %

EVIO's FCF Margin for the quarter that ended in Jun. 2020 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2020 )/Revenue (Q: Jun. 2020 )
=-0.054/0.603
=-8.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -8.96% mean?
EVIO (EVIO) has a FCF Margin % of -8.96% as of Jun. 2020. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EVIO and its competitors.
Is EVIO's FCF Margin % too high?
EVIO's current FCF Margin % is -8.96%.
How does EVIO's FCF Margin % compare to VCBD and ACCA?
EVIO's FCF Margin % of -8.96% can be compared against companies in the Drug Manufacturers industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EVIO and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EVIO's current FCF Margin % is -8.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EVIO stock overvalued right now?
EVIO (EVIO) has a current FCF Margin % of -8.96%. The current FCF Margin % is -8.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For EVIO (EVIO), the current FCF Margin % is -8.96% as of Jun. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EVIO Business Description

Address 2654 W. Horizon Ridge Drive Parkway, Suite B5-208, Henderson, NV, USA, 89052
EVIO Inc is a Colorado corporation and a diversified holding company. Its subsidiaries provide analytical testing and advisory services to the emerging legalized cannabis industry. The Company performs analytical testing for cannabis and cannabis-derived products, including hemp and CBD products. Its current operations also include pharmaceutical, environmental, stability, and analytical testing, as well as residential and commercial construction and investments, with operations in the United States and Canada.